Illinois General Assembly - Bill Status for EO2401

Contains findings concerning sickle cell disease, costs associated with treatment of sickle cell disease, and state and federal efforts to make innovative sickle cell therapies more widely available. Directs the Department of Healthcare and Family Services to lead the State’s efforts to establish payment models and financing structures that support access to new sickle cell disease treatments and high-cost drugs through the Illinois Medicaid Program. Establishes the Advisory Council on Financing Access to Sickle Cell Disease Treatment and Other High Cost Drugs and Treatments. Describes the duties and composition of the Advisory Council. Directs the Advisory Council to report its findings to the Governor and General Assembly by no later than December 31, 2024. Specifies that the report is to evaluate options for financing various new drugs and therapies for the treatment of sickle cell disease and recommend strategies to equitably provide access to these new treatments. Authorizes certain members of the Advisory Council to receive an honorarium of up to $250 for each of the 4 meetings required under the Executive Order. Specifies that members of the Advisory Councill shall serve at the will of the Governor. Authorizes the Governor to fill vacancies on the Advisory Council by appointment. Provides for the termination of the Advisory Council on December 31, 2024. Provides that the Advisory Council is subject to the Open Meetings Act and the Freedom of Information Act. Directs the Department of Healthcare and Family Services to provide administrative support to the Advisory Council. Specifies that the Executive Order is not to be construed to contravene any federal or state law or regulation. Supersedes any contrary provision of any prior executive orders. Effective immediately.

×